VYGR
Voyager Therapeutics, Inc.
Set alert
- YTD
- -56.23%
- 1 year
- -61.95%
- Open
- 1.75
- Prev close
- 1.76
- Mkt cap
- 105.98M
- Vol
- 878.83K
- Avg vol
- 654.75K
- EPS
- -1.81
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.68
- High
- 1.76
- Forward P/E
- -3.41
- Beta
- 0.89
- Short ratio
- 4.44
- Inst. own
- 65.52%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 6.52
- 200-d avg
- 7.56
- 1y target
- 17.10
Key statistics
- Market cap
- 313.00M
- Enterprise value
- 14.08M
- Trailing P/E
- 8.68
- Forward P/E
- -3.41
- PEG ratio
- 0.00
- Price / sales
- 1.91
- Price / book
- 0.95
- EPS (TTM)
- 0.66
- Beta
- 0.89
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 15.80%
- Revenue (TTM)
- 163.78M
- Revenue growth
- 433.80%
- Free cash flow
- -19.75M
- Total cash
- 345.36M
- Total debt
- 45.35M
- Return on equity
- 10.22%
- Shares outstanding
- 54.63M
- Short % of float
- 5.58%
- 50-day average
- 6.52
- 200-day average
- 7.56
Analyst view
Consensus: none
- Target (low)
- 11.00
- Target (mean)
- 17.10
- Target (high)
- 30.00
- Strong buy1
- Buy9
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.34035.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.45 | -0.16 | +0.29 | +64.44% |
| Aug 6, 2024 | Jun 1, 2024 | -0.38 | -0.18 | +0.20 | +52.63% |
| May 13, 2024 | Mar 1, 2024 | -0.44 | -0.20 | +0.24 | +54.55% |
| Feb 28, 2024 | Dec 1, 2023 | -0.59 | 1.25 | +1.84 | +311.86% |
| Nov 6, 2023 | Sep 1, 2023 | -0.58 | -0.59 | -0.01 | -1.72% |
| Aug 3, 2023 | Jun 1, 2023 | -0.59 | -0.51 | +0.08 | +13.56% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 2, 2024 | Citigroup | init | — | Buy |
| Nov 14, 2024 | Canaccord Genuity | main | Buy | Buy |
| Nov 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 24, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 16, 2024 | Leerink Partners | init | — | Outperform |
| Aug 20, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Voyager Therapeutics, Inc.
Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- voyagertherapeutics.com
News
- Voyager's Tau-Targeted Gene Therapy VY1706 and Anti-Tau Antibody VY7523 for Alzheimer's Disease to Be Featured in Poster Presentations at CTAD 2026
- Voyager Therapeutics Appoints Robin Swartz As President, Effective October 20, And Is Expected To Become CEO In Q1 2027
- HC Wainwright & Co. Reiterates Buy on Voyager Therapeutics, Maintains $25 Price Target
- Voyager Therapeutics Q2 EPS $(0.40) Beats $(0.48) Estimate, Sales $3.165M Miss $4.728M Estimate
- Voyager Therapeutics Presents Six‑Month Toxicology Data At AAIC Showing Investigational Alzheimer’s Gene Therapy VY1706 Was Well Tolerated And Cut Tau Protein Up To 75% In Primates
- Jim Cramer: TE Connectivity Is ‘Terrific,’ Buy This Industrial Stock
- Voyager Therapeutics Issued FDA Clearance For Its Investigational New Drug Application For VY1706 To Treat Alzheimer's Disease
- 12 Health Care Stocks Moving In Thursday's After-Market Session
- Voyager Therapeutics Q1 EPS $(0.47) Beats $(0.53) Estimate, Sales $2.593M Miss $8.784M Estimate
- Voyager Therapeutics To Present Eight Oral And Poster Studies At ASGCT 2026, Including Late‑Breaking GLP Toxicology Data On Investigational Tau‑Silencing Alzheimer's Gene Therapy VY1706 Ahead Of Planned IND Filing In Q2 And First‑In‑Human Dosing In H2 2026
Your note
Sign in to keep a note on VYGR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CARTER TODD ALFRED | Officer | Sale | Feb 20, 2024 | 87,627 |
| FAHEY SANDELL JACQUELYN | Officer | Sale | Oct 1, 2024 | 86,001 |
| FERGUSON TOBY | Officer | Stock Award(Grant) | Mar 31, 2024 | 105,000 |
| HESSLEIN ROBERT W | General Counsel | Sale | Mar 19, 2023 | 102,200 |
| JORGENSEN NATHAN D. | Chief Financial Officer | Stock Award(Grant) | Sep 30, 2024 | 80,000 |
| NEUROCRINE BIOSCIENCE INC | Beneficial Owner of more than 10% of a Class of Security | Purchase | Feb 22, 2023 | 8,575,320 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 9.94% | 5,430,430 | 31.12M | Sep 29, 2024 |
| Armistice Capital, LLC | 9.52% | 5,200,000 | 29.80M | Sep 29, 2024 |
| EcoR1 Capital, LLC | 7.17% | 3,917,546 | 22.45M | Sep 29, 2024 |
| Vanguard Group Inc | 5.83% | 3,186,427 | 18.26M | Sep 29, 2024 |
| Farallon Capital Management LLC | 4.20% | 2,292,000 | 13.13M | Sep 29, 2024 |
| Dimensional Fund Advisors LP | 2.02% | 1,105,044 | 6.33M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3.14% | 1,713,895 | 9.82M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.21% | 1,206,285 | 6.91M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.18% | 646,396 | 3.70M | Sep 29, 2024 |
| Price (T.Rowe) Health Sciences Fund | 1.14% | 622,401 | 3.57M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.86% | 469,640 | 2.69M | Aug 30, 2024 |
| Vanguard Explorer Fund, Inc. | 0.84% | 457,063 | 2.62M | Jul 30, 2024 |